Does ACEI or ARB therapy reduce LV mass and cardiovascular events in patients receiving hemodialysis?
In hemodialysis patients, ACEI or ARB therapy reduces LV mass but current evidence does not show a significant reduction in fatal and nonfatal cardiovascular events.
Treatment with an ACEI or ARB reduced LV mass in patients receiving HD. However, their use was not associated with a statistically significant reduction in the risk of fatal and nonfatal CV events. Larger, high-quality trials in the HD population are required to determine if the effects of ACEI or ARB therapy on LV mass translate into decreased CV morbidity and mortality.
Tai et al. (Fri,) studied this question.